Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the completion of the transaction, the chief operating officer now owns 1,116,345 shares in the company, valued at $11,409,045.90. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96.
• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The stock was sold at an average price of $11.06, for a total transaction of $3,489,673.32.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22.

Roivant Sciences Stock Performance

ROIV traded up $0.01 during trading on Friday, reaching $11.01. The company's stock had a trading volume of 8,016,575 shares, compared to its average volume of 5,462,047. The company has a market capitalization of $7.86 billion, a price-to-earnings ratio of -73.40 and a beta of 1.25. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The company's fifty day moving average price is $10.34 and its 200-day moving average price is $11.14.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Institutional Trading of Roivant Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC grew its position in Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after acquiring an additional 75,609 shares during the period. Virtu Financial LLC purchased a new stake in shares of Roivant Sciences during the 3rd quarter valued at about $207,000. Te Ahumairangi Investment Management Ltd grew its holdings in Roivant Sciences by 19.9% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company's stock valued at $2,313,000 after purchasing an additional 33,467 shares in the last quarter. Tyro Capital Management LLC grew its stake in shares of Roivant Sciences by 0.6% during the third quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company's stock valued at $20,252,000 after acquiring an additional 10,649 shares in the last quarter. Finally, Retirement Systems of Alabama lifted its stake in shares of Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after acquiring an additional 112,286 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ROIV shares. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.